𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Neoadjuvant therapy with imatinib mesylate for locally advanced GI stromal tumor

✍ Scribed by Janak N. Shah; Weijing Sun; Raja R. Seethala; Virginia A. LiVolsi; Robert D. Fry; Gregory G. Ginsberg

Book ID
118525234
Publisher
Elsevier Science
Year
2005
Tongue
English
Weight
247 KB
Volume
61
Category
Article
ISSN
1097-6779

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Systemic therapy for advanced gastrointe
Systemic therapy for advanced gastrointestinal stromal tumors: Beyond imatinib
✍ Edward J. Kim; Mark M. Zalupski πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 88 KB

## Abstract Progression on first‐line therapy with imatinib in gastrointestinal stromal tumors (GIST) is caused by either initial resistance or more often a secondary mutation in tyrosine kinases KIT or PDGFR. Therapies in development for imatinib‐resistant GIST include agents that target KIT/PDGFR